Transgenic T-cell receptor immunotherapy for cancer: building on clinical success

by Natasha Oppermans, Gray Kueberuwa, Robert E. Hawkins, John S. Bridgeman
Published 2020-06-01

Cellular-level versus receptor-level response threshold hierarchies in T-cell activation

by Hugo Antonius van den Berg, Kristin eLadell, Kelly eMiners, Bruno eLaugel, Sian eLlewellyn-Lacey, Mathew eClement, David K Cole, Emma eGostick, Linda eWooldridge, Andrew Kelvin Sewell, John Stephen Bridgeman, David A Price, David A Price
Published 2013-09-01

Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1‐specific CD8+ T cells

by Frances E Pearson, Kirsteen M Tullett, Ingrid M Leal‐Rojas, Oscar L Haigh, Kelly‐Anne Masterman, Carina Walpole, John S Bridgeman, James E McLaren, Kristin Ladell, Kelly Miners, Sian Llewellyn‐Lacey, David A Price, Antje Tunger, Marc Schmitz, John J Miles, Mireille H Lahoud, Kristen J Radford
Published 2020-01-01

Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope

by David K. Cole, Anna Fuller, Garry Dolton, Efthalia Zervoudi, Mateusz Legut, Kim Miles, Lori Blanchfield, Florian Madura, Christopher J. Holland, Anna M. Bulek, John S. Bridgeman, John J. Miles, John J. Miles, Andrea J. A. Schauenburg, Konrad Beck, Brian D. Evavold, Pierre J. Rizkallah, Andrew K. Sewell
Published 2017-11-01